论文部分内容阅读
激素受体阳性的浸润性乳腺癌患者,雌激素受体(estrogen receptor,ER)的调节是全身治疗的重要组成部分。大约3/4的浸润性乳腺癌患者激素受体阳性,而雌激素受体通路是肿瘤细胞生长的关键,对于所有ER阳性的患者,选择性雌激素受体调节剂他莫西芬(tamoxifen,TAM)是绝经前及绝经后乳腺癌患者传统的内分泌辅助治疗,但最近的试验研究显示芳香化酶抑制剂(aromatase inhibitors,AIs)对绝经后乳腺癌患者的治疗颇具优势。本文综述了绝经后乳腺癌患者内分泌治疗进展。
Hormone receptor-positive invasive breast cancer, estrogen receptor (estrogen receptor, ER) regulation is an important part of systemic therapy. About three-fourths of patients with invasive breast cancer are hormone receptor positive, whereas the estrogen receptor pathway is the key to tumor cell growth. For all ER-positive patients, the selective estrogen receptor modulator tamoxifen TAM) is a traditional endocrine adjuvant therapy in premenopausal and postmenopausal women with breast cancer. However, recent experimental studies have shown that aromatase inhibitors (AIs) have advantages in the treatment of postmenopausal women with breast cancer. This article reviews the progress of endocrine therapy in postmenopausal women with breast cancer.